CMPX Key Statistics, Chart & Performance
The current stock price of CMPX is 5.39 USD. In the past month the price increased by 42.59%. In the past year, price increased by 230.68%.
CMPX Latest News, Press Relases and Analysis
CMPX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.09 | 402.18B | ||
| AMGN | AMGEN INC | 15.76 | 185.50B | ||
| GILD | GILEAD SCIENCES INC | 15.57 | 158.22B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.89 | 110.80B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.43 | 83.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 872.78 | 58.35B | ||
| INSM | INSMED INC | N/A | 43.23B | ||
| NTRA | NATERA INC | N/A | 32.54B | ||
| BIIB | BIOGEN INC | 10.87 | 26.67B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.51 | 22.09B | ||
| INCY | INCYTE CORP | 16.46 | 20.63B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.21B |
Related stock screener links
About CMPX
Company Profile
Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of proprietary antibody therapeutics. The company is headquartered in Boston, Massachusetts and currently employs 35 full-time employees. The company went IPO on 2020-11-13. The firm is developing proprietary antibody-based therapeutics to treat multiple human diseases. Its pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. Its lead product candidate, tovecimig, is a bispecific antibody targeting Delta-like ligand 4 (DLL4), a ligand of Notch-1, and vascular endothelial growth factor A (VEGF-A). Its second program, CTX-471, is an agonistic antibody targeting a member of the tumor necrosis factor receptor superfamily member 9 (TNFRSF9), also known as CD-137, a co-stimulatory receptor which is mostly expressed on activated, but not on resting T-cells and NK cells. Its third program, CTX-8371, is a bispecific antibody targeting the programmed cell death protein-1 (PD-1), an inhibitory immune checkpoint receptor, and its ligand PD-L1, two validated immune-oncology targets.
Company Info
COMPASS THERAPEUTICS INC
80 Guest Street
Boston MASSACHUSETTS US
Employees: 35
Phone: 16175008099
COMPASS THERAPEUTICS INC / CMPX FAQ
What does CMPX do?
Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of proprietary antibody therapeutics. The company is headquartered in Boston, Massachusetts and currently employs 35 full-time employees. The company went IPO on 2020-11-13. The firm is developing proprietary antibody-based therapeutics to treat multiple human diseases. Its pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. Its lead product candidate, tovecimig, is a bispecific antibody targeting Delta-like ligand 4 (DLL4), a ligand of Notch-1, and vascular endothelial growth factor A (VEGF-A). Its second program, CTX-471, is an agonistic antibody targeting a member of the tumor necrosis factor receptor superfamily member 9 (TNFRSF9), also known as CD-137, a co-stimulatory receptor which is mostly expressed on activated, but not on resting T-cells and NK cells. Its third program, CTX-8371, is a bispecific antibody targeting the programmed cell death protein-1 (PD-1), an inhibitory immune checkpoint receptor, and its ligand PD-L1, two validated immune-oncology targets.
What is the stock price of COMPASS THERAPEUTICS INC today?
The current stock price of CMPX is 5.39 USD. The price increased by 7.58% in the last trading session.
Does CMPX stock pay dividends?
CMPX does not pay a dividend.
How is the ChartMill rating for COMPASS THERAPEUTICS INC?
CMPX has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the Price/Earnings (PE) ratio of COMPASS THERAPEUTICS INC (CMPX)?
COMPASS THERAPEUTICS INC (CMPX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.45).
Is COMPASS THERAPEUTICS INC (CMPX) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on CMPX.
What is COMPASS THERAPEUTICS INC worth?
COMPASS THERAPEUTICS INC (CMPX) has a market capitalization of 958.67M USD. This makes CMPX a Small Cap stock.
CMPX Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to CMPX. When comparing the yearly performance of all stocks, CMPX is one of the better performing stocks in the market, outperforming 98.18% of all stocks.
CMPX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CMPX. CMPX has a great financial health rating, but its profitability evaluates not so good.
CMPX Financial Highlights
Over the last trailing twelve months CMPX reported a non-GAAP Earnings per Share(EPS) of -0.45. The EPS decreased by -21.62% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -21.35% | ||
| ROE | -23.56% | ||
| Debt/Equity | 0 |
CMPX Forecast & Estimates
17 analysts have analysed CMPX and the average price target is 12.98 USD. This implies a price increase of 140.85% is expected in the next year compared to the current price of 5.39.
For the next year, analysts expect an EPS growth of -49.04% and a revenue growth -100% for CMPX